News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Weather
E-Edition
Subscribe
Sign Up For Newsletters
News
News
Local News
Crime & Public Safety
Your Tax Dollars At Work
Politics
Massachusetts
Nation
World
Business
Health
Weather
Columnists
Traffic
Sports
Sports
Red Sox
Patriots
Celtics
Bruins
College
High School
More Sports
Scores & Stats
Entertainment
Entertainment
Celebrity News
Arts & Culture
Movies
Television
Music
Fun & Games
Horoscope
Lottery
Comics
Puzzles
Lifestyle
Lifestyle
Food & Beverage
Travel
Style & Fashion
Obituaries
Obituaries
Local Obituaries
Submit an Obituary
Opinion
Opinion
Editorials
Op-Ed
Letters
Submit a Letter
Radio
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Alpine Immune Sciences, Inc.
< Previous
1
2
Next >
Alpine Immune Sciences Reports First Quarter 2024 Financial Results
May 09, 2024
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy
April 10, 2024
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
April 10, 2024
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
VRTX
Alpine Immune Sciences to Present Updated Clinical Data for Povetacicept in IgA Nephropathy at the World Congress of Nephrology 2024
April 01, 2024
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024
March 21, 2024
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences to Participate in Upcoming H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
March 20, 2024
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Provides Corporate Update and Full Year 2023 Financial Results
March 18, 2024
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences to Report Fourth Quarter and Full Year 2023 Financial Results
March 07, 2024
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
February 26, 2024
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
February 01, 2024
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Announces Amendment of Acazicolcept Option and License Agreement with AbbVie
December 21, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 18, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences to Participate in the Evercore ISI HealthconX Conference
November 20, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Presents New Translational Data on Povetacicept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023
November 15, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Reports Third Quarter 2023 Financial Results
November 14, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Presents New Translational Data on Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023
November 13, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Announces Pricing of $150 Million Public Offering
November 06, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Announces Proposed Public Offering
November 06, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Presents New Preclinical Data on Povetacicept in Myasthenia Gravis at the American Association of Neuromuscular & Electrodiagnostic Medicine 2023 Annual Meeting
November 03, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late-Breaking Poster Session at the American Society of Nephrology Kidney Week 2023
November 02, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences to Present New Translational Data on Povetacicept and Acazicolcept in Systemic Lupus Erythematosus at American College of Rheumatology Convergence 2023
October 30, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences to Present Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late Breaker Poster Session at American Society of Nephrology Kidney Week 2023
October 13, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Announces Appointment of Wolfgang Dummer, M.D., Ph.D., as Chief Medical Officer and Grant under Nasdaq Listing Rule 5635(c)
October 04, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Presents First Preclinical Data for Povetacicept in Myasthenia Gravis at the American Neurological Association Annual Meeting
September 12, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences to Participate in Two Upcoming Healthcare Conferences
September 05, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Announces Initiation of Dosing in 240 mg IgA Nephropathy Cohort of Povetacicept Clinical Study (RUBY-3)
August 30, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Announces Appointment of M. Christina Yi as Chief Technology Officer and Grant under Nasdaq Listing Rule 5635(c)
August 22, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Reports Second Quarter 2023 Financial Results
August 14, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences to Present Data from RUBY-1, a Phase 1 Study of Povetacicept, at Upcoming Scientific Congresses
May 19, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
Alpine Immune Sciences Reports First Quarter 2023 Financial Results
May 11, 2023
From
Alpine Immune Sciences, Inc.
Via
Business Wire
Tickers
ALPN
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close